Contributions
Abstract: P947
Type: Poster Sessions
Abstract Category: Therapy - Tools for detecting therapeutic response
Introduction: Biotin is a coenzyme for carboxylases that participates in the tricarboxylic acid (Krebs) cycle required for adenosine triphosphate (ATP) production. High-dose oral biotin has been recently proposed in patients with progressive multiple sclerosis (MS).
Brain phosphorous magnetic resonance spectroscopy (31P-MRS) allows for the evaluation of the concentration of ATP metabolites, while diffusion tensor imaging (DTI) parameters such as fractional anisotropy, axial and radial diffusivities may be of use to assess myelin integrity.
Objectives: We aimed at evaluating whether high-dose oral biotin could increase ATP production and myelin synthesis in patients with progressive MS using phosphorous magnetic resonance spectroscopy ( 31P-MRS) and DTI respectively.
Methods: 31P-MRS and DTI were performed at 3T in 19 patients with progressive MS, before (M0) and after a 12-month period (M12) of treatment by high-dose oral biotin (100 mg thrice a day). Using 31P-MRS, measurements of ATP metabolites were made in the fronto-parietal normal appearing white matter (NAWM). DTI parameters were measured after tractography of the whole brain fibers.
Expanded disability status scale (EDSS), 10-meter walk test (10mWT), 31P-MRS and DTI parameters were compared between M0 and M12 using the Wilcoxon test.
Results: The EDSS score and the 10mWT performance did not show any change at M12 compared to M0 (p=0.06 and p=0.84, respectively). There was also no statistical difference for ATP metabolite measurements (p=0.43), as well as DTI parameters (p=0.66).
Conclusions: One year treatment with high-dose biotin in progressive MS patients did not yield any significant changes in clinical, 31P-MRS or DTI parameters. Further studies with a long-term follow-up are required to draw more formal conclusions.
Disclosure: The authors have nothing to disclose
Abstract: P947
Type: Poster Sessions
Abstract Category: Therapy - Tools for detecting therapeutic response
Introduction: Biotin is a coenzyme for carboxylases that participates in the tricarboxylic acid (Krebs) cycle required for adenosine triphosphate (ATP) production. High-dose oral biotin has been recently proposed in patients with progressive multiple sclerosis (MS).
Brain phosphorous magnetic resonance spectroscopy (31P-MRS) allows for the evaluation of the concentration of ATP metabolites, while diffusion tensor imaging (DTI) parameters such as fractional anisotropy, axial and radial diffusivities may be of use to assess myelin integrity.
Objectives: We aimed at evaluating whether high-dose oral biotin could increase ATP production and myelin synthesis in patients with progressive MS using phosphorous magnetic resonance spectroscopy ( 31P-MRS) and DTI respectively.
Methods: 31P-MRS and DTI were performed at 3T in 19 patients with progressive MS, before (M0) and after a 12-month period (M12) of treatment by high-dose oral biotin (100 mg thrice a day). Using 31P-MRS, measurements of ATP metabolites were made in the fronto-parietal normal appearing white matter (NAWM). DTI parameters were measured after tractography of the whole brain fibers.
Expanded disability status scale (EDSS), 10-meter walk test (10mWT), 31P-MRS and DTI parameters were compared between M0 and M12 using the Wilcoxon test.
Results: The EDSS score and the 10mWT performance did not show any change at M12 compared to M0 (p=0.06 and p=0.84, respectively). There was also no statistical difference for ATP metabolite measurements (p=0.43), as well as DTI parameters (p=0.66).
Conclusions: One year treatment with high-dose biotin in progressive MS patients did not yield any significant changes in clinical, 31P-MRS or DTI parameters. Further studies with a long-term follow-up are required to draw more formal conclusions.
Disclosure: The authors have nothing to disclose